US2026048057A1PendingUtilityA1

Anti-ischemic compositions

60
Assignee: FAGRELL BENGTPriority: Aug 5, 2019Filed: Oct 24, 2025Published: Feb 19, 2026
Est. expiryAug 5, 2039(~13 yrs left)· nominal 20-yr term from priority
Inventors:FAGRELL BENGTPARKER JEFFREY GOLSSON NILS U
A61K 38/012A61K 9/16A01N 1/126A61P 7/08A61K 31/519A61K 35/62A61K 38/42A61K 38/05A61P 9/10
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described herein are compositions for use in medicine as anti-ischemic organ storage and perfusion solutions.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of preparing a composition, comprising:
 combining a purified erythrocruorin with 5-methyltetrahydrofolate, 5-formyltetrahydrofolate, or 5-methyltetrahydrofolate and 5-formyltetrahydrofolate, and optionally 5,6,7,8-tetrahydrobiopterin.   
     
     
         2 . The method of  claim 1 , wherein the composition is stored as a liquid. 
     
     
         3 . The method of  claim 1 , wherein the composition is reduced to a paste. 
     
     
         4 . The method of  claim 1 , wherein the composition is lyophilized to a powder. 
     
     
         5 . The method of  claim 1 , wherein the purified erythrocruorin is combined with 0.001 to 500 μmol/L 5-methyltetrahydrofolate and 0.001 to 500 μmol/L 5,6,7,8-tetrahydrobiopterin. 
     
     
         6 . The method of  claim 5 , wherein the composition is stored as a liquid. 
     
     
         7 . The method of  claim 5 , wherein the composition is reduced to a paste. 
     
     
         8 . The method of  claim 5 , wherein the composition is lyophilized to a powder. 
     
     
         9 . The method of  claim 1 , wherein the purified erythrocruorin is combined with 0.001 to 500 μmol/L 5-formyltetrahydrofolate and 0.001 to 500 μmol/L 5,6,7,8-tetrahydrobiopterin. 
     
     
         10 . The method of  claim 9 , wherein the composition is stored as a liquid. 
     
     
         11 . The method of  claim 9 , wherein the composition is reduced to a paste. 
     
     
         12 . The method of  claim 9 , wherein the composition is lyophilized to a powder. 
     
     
         13 . The method of  claim 1 , wherein the purified erythrocruorin is combined with 0.001 to 500 μmol/L 5-methyltetrahydrofolate, 0.001 to 500μmol/L 5-formyltetrahydrofolate and 0.001 to 500 μmol/L 5,6,7,8-tetrahydrobiopterin. 
     
     
         14 . The method of  claim 13 , wherein the composition is stored as a liquid. 
     
     
         15 . The method of  claim 13 , wherein the composition is reduced to a paste. 
     
     
         16 . The method of  claim 13 , wherein the composition is lyophilized to a powder. 
     
     
         17 . The method of  claim 1 , wherein the purified erythrocruorin is a purified annelid erythrocruorin. 
     
     
         18 . The method of  claim 1 , wherein the purified erythrocruorin is a purified arthropod erythrocruorin. 
     
     
         19 . The method of  claim 1 , wherein the purified erythrocruorin is a purified insect erythrocruorin. 
     
     
         20 . The method of  claim 1 , wherein the purified erythrocruorin is a purified  Lumbricus terrestris  erythrocruorin.

Join the waitlist — get patent alerts

Track US2026048057A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.